All Stories

  1. Outcomes and Prognostic Factors in a Large Cohort of Hospitalized Cancer Patients With COVID-19
  2. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study
  3. Indocyanine green imaging to guide lymphadenectomy in laparoscopic distal gastrectomy - With vídeo
  4. Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer
  5. Supercharged cervical anastomosis for esophagectomy and gastric pull-up
  6. Thoracoscopic esophagectomy is related to better outcomes in early adenocarcinoma of esophagogastric junction tumors
  7. Early outcomes and complications following cardiac surgery in patients testing positive for coronavirus disease 2019: An international cohort study
  8. Cytotoxic T‐lymphocyte‐associated protein 4 in gastric cancer: Prognosis and association with PD‐L1 expression
  9. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: the COVIDSurg mortality score
  10. Laparoscopic Completion Total Gastrectomy for Remnant Gastric Cancer
  11. Laparoscopic gastrectomy for early and advanced gastric cancer in a western center: a propensity score-matched analysis
  12. UNDERWATER ENDOSCOPIC MUCOSAL RESECTION FOR SMALL RECTAL NEUROENDOCRINE TUMORS
  13. Epstein–Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy
  14. Remnant gastric cancer: An ordinary primary adenocarcinoma or a tumor with its own pattern?
  15. Brazilian Group of Gastrointestinal Tumours’ consensus guidelines for the management of oesophageal cancer
  16. IMPACT OF AGING IN THE SURGICAL OUTCOMES OF GASTRIC CANCER PATIENTS
  17. Predictive factors of recurrence in adenocarcinoma of the esophagogastric junction in the multimodal era
  18. Diagnosis of Clinical Complete Response by Probe-Based Confocal Laser Endomicroscopy (pCLE) After Chemoradiation for Advanced Rectal Cancer
  19. Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study
  20. Endoscopy infection control strategy during the COVID-19 pandemic: experience from a tertiary cancer center in Brazil
  21. Impact of COVID-19 pandemic on the surgical treatment of gastric cancer
  22. Impact of telephone monitoring on cancer patients undergoing esophagectomy and gastrectomy
  23. Is it Safe to Perform Elective Colorectal Surgical Procedures during the COVID-19 Pandemic? A Single Institution Experience with 103 Patients
  24. Management of Respiratory Failure Caused by COVID-19 after Thoracoscopic Esophagectomy
  25. Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)
  26. RECURRENCE IN PN0 GASTRIC CANCER: RISK FACTORS IN THE OCCIDENT
  27. Prognostic value of 18F-fluorodeoxyglucose PET/computed tomography metabolic parameters measured in the primary tumor and suspicious lymph nodes before neoadjuvant therapy in patients with esophageal carcinoma
  28. Preoperative nasopharyngeal swab testing and postoperative pulmonary complications in patients undergoing elective surgery during the SARS-CoV-2 pandemic
  29. Long‐term outcomes of endoscopic submucosal dissection and transanal endoscopic microsurgery for the treatment of rectal tumors
  30. D2 Lymphadenectomy According to the Arterial Variations in Gastric and Hepatic Irrigation
  31. EUS-guided gastroenterostomy: Initial experience in a brazilian tertiary center
  32. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer
  33. Brazilian Group of Gastrointestinal Tumours’ consensus guidelines for the management of gastric cancer
  34. Laparoscopic vs open colorectal surgery
  35. Immunohistochemical Scores for Programmed Death Ligand-1 (PD-L1) Expression and Prognostic in Patients with Gastric Cancer
  36. Remnant Gastric Cancer: Neglect Group with High Potential for Immunotherapy
  37. Delaying surgery for patients with a previous SARS-CoV-2 infection
  38. Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus
  39. Small-bowel cryptococcosis diagnosed by double-balloon endoscopy in patient without human immunodeficiency virus
  40. Remnant gastric cancer: a neglected group with high potential for immunotherapy
  41. Gastric Remnant Carcinosarcoma: Case Report and Review of the Literature
  42. Persistent postoperative ascites successfully identified and treated with laparoscopic indocyanine green fluorescence
  43. Underwater endoscopic resection of an ileal neuroendocrine tumor
  44. Prediction scores for complication and recurrence after multivisceral resection in gastric cancer
  45. Transhiatal laparoscopic esophagectomy with extended lymphadenectomy guided by green-indocyanine imaging for adenocarcinoma of the esophagogastric junction
  46. UNDERWATER ENDOSCOPIC MUCOSAL RESECTION FOR NON-PEDUNCULATED COLORECTAL LESIONS. A PROSPECTIVE SINGLE-ARM STUDY
  47. Safety and costs analysis of early hospital discharge after brain tumour surgery: a pilot study
  48. Validation and improvement of the predictive equation for resting energy expenditure in advanced gastrointestinal cancer
  49. Diaphragmatic Hernia Repair After Esophagectomy: Technical Report and Lessons After a Series of Cases
  50. Multivisceral resection vs standard gastrectomy for gastric adenocarcinoma
  51. Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A case‐control study
  52. BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 1): AN UPDATE ON DIAGNOSIS, STAGING, ENDOSCOPIC TREATMENT AND FOLLOW-UP
  53. Cancer pain treatment during the COVID-19 pandemic: institutional recommendations
  54. Esophagectomy in a patient with pulmonary histoplasmosis: A case report of surgical aspects and complications (with video)
  55. GASTRECTOMY IN OCTOGENARIANS WITH GASTRIC CANCER: IS IT FEASIBLE?
  56. How should health systems prepare for the evolving COVID-19 pandemic? Reflections from the perspective of a Tertiary Cancer Center
  57. Impact of enteroscopy on diagnosis and management of small bowel tumors
  58. INTESTINAL PERFORATION CAUSED BY COVID-19
  59. Long-term survival analysis after endoscopic stenting as a bridge to surgery for malignant colorectal obstruction: comparison with emergency diverting colostomy
  60. Post-esophagectomy Symptomatic Dunbar Syndrome: A rare diagnosis of abdominal pain after surgery
  61. ROBOTIC GASTRECTOMY: TECHNIQUE STANDARDIZATION
  62. Surgical results of remnant gastric cancer treatment
  63. Gastric partitioning for the treatment of malignant gastric outlet obstruction
  64. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype?
  65. Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer
  66. The value of cellular components of blood in the setting of trimodal therapy for esophageal cancer
  67. Schistosomiasis Misleading Gastric Cancer Treatment
  68. Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients
  69. Neutrophil-lymphocyte ratio change after curative gastrectomy for gastric cancer: a subgroup analysis
  70. Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus
  71. Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1
  72. LYMPHOCYTE COUNT AND PLATELET VOLUME PREDICTS POSTOPERATIVE COMPLICATIONS IN ESOPHAGECTOMY FOR CANCER: A COHORT STUDY
  73. Two-step ESD: an option for en-bloc resection of extensive colorectal laterally spreading tumors
  74. Induction Chemotherapy for Locally Advanced Esophageal Cancer
  75. Esophagojejunal anastomotic fistula: a major issue after radical total gastrectomy
  76. Clinical and endoscopic aspects of metastases to the gastrointestinal tract
  77. The Clinical and Economic Burden of Colorectal Anastomotic Leaks: Middle-Income Country Perspective
  78. Role of Magnification Chromoendoscopy in the Management of Colorectal Neoplastic Lesions Suspicious for Submucosal Invasion
  79. Laparoscopic D2 Gastrectomy for Gastric Cancer: Mid-Term Results and Current Evidence
  80. Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil
  81. Surgical outcomes of gastrectomy with D1 lymph node dissection performed for patients with unfavorable clinical conditions
  82. Anatomical topography of the tumor is related to prognostic survival in adenocarcinoma of esophagogastric junction?: Multivariable analysis.
  83. Diagnostic performance of magnetic resonance to assess treatment response after neoadjuvant therapy in patients with locally advanced rectal cancer
  84. TOTAL OMENTECTOMY IN GASTRIC CANCER SURGERY: IS IT ALWAYS NECESSARY?
  85. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study
  86. CONVERSION THERAPY FOR GASTRIC CANCER: EXPANDING THE TREATMENT POSSIBILITIES
  87. Câncer gástrico em adultos jovens: um grupo de pior prognóstico?
  88. Surgical Management of Malignant Intestinal Obstruction: Outcome and Prognostic Factors
  89. TRANSHIATAL ESOPHAGECTOMY IS NOT ASSOCIATED WITH POOR QUALITY LYMPHADENECTOMY
  90. Association between Polymorphisms in Inflammatory Response-Related Genes and the Susceptibility, Progression and Prognosis of the Diffuse Histological Subtype of Gastric Cancer
  91. Risk assessment of lymph node metastases in early gastric adenocarcinoma fulfilling expanded endoscopic resection criteria
  92. Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis Refractory to Endoscopic Treatment with Dilatation in Patients Treated for Head and Neck Cancer
  93. Comparison of laparoscopic versus open surgery for rectal cancer: outcomes and cost analysis
  94. The 2018 ISDE achalasia guidelines
  95. Lymph Node Yield After Neoadjuvant Chemoradiotherapy in Rectal Cancer Specimens: A Randomized Trial Comparing Two Fixatives
  96. Pathologic complete response implies a fewer number of lymph nodes in specimen of rectal cancer patients treated by neoadjuvant therapy and total mesorectal excision
  97. Risk factors associated with the development of gastric cancer — case-control study
  98. Reply to: “Association between neutrophil-lymphocyte ratio and prognosis after potentially curative resection for gastric cancer”
  99. HEALTH-RELATED QUALITY OF LIFE ASSESSMENT IN PATIENTS WITH RECTAL CANCER TREATED WITH CURATIVE INTENT
  100. Effect of postoperative goal-directed therapy in cancer patients undergoing high-risk surgery: a randomized clinical trial and meta-analysis
  101. Predictors of major complications after elective abdominal surgery in cancer patients
  102. Duodenal fistula: The most lethal surgical complication in a case series of radical gastrectomy
  103. Risk factors for advanced duodenal and ampullary adenomatosis in familial adenomatous polyposis: a prospective, single-center study
  104. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer
  105. Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer
  106. Variables Associated to Pathologic Complete Response, Overall Survival and Disease-Free Survival in the Neoadjuvant Setting for Esophageal Cancer: A Retrospective Cohort Analysis
  107. Advanced age does not increase morbidity in pancreaticoduodenectomy
  108. Self-expandable metal stent for malignant esophagorespiratory fistula: predictive factors associated with clinical failure
  109. Surgical treatment of gastric cancer: a 10-year experience in a high-volume university hospital
  110. Validation of classic and expanded criteria for endoscopic submucosal dissection of early gastric cancer: 7 years of experience in a Western tertiary cancer center
  111. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy
  112. Probe-based confocal endomicroscopy is accurate for differentiating gastric lesions in patients in a Western center
  113. Prognostic Role of Neutrophil/Lymphocyte Ratio in Resected Gastric Cancer: A Systematic Review and Meta-analysis
  114. Early mobilization programme improves functional capacity after major abdominal cancer surgery: a randomized controlled trial
  115. CHARACTERIZATION OF THE MUCIN PHENOTYPE CAN PREDICT GASTRIC CANCER RECURRENCE AFTER ENDOSCOPIC MUCOSAL RESECTION
  116. Erratum to: One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer
  117. Outcomes of Immediate Internal Pudendal Artery Perforator Flap Reconstruction for Irradiated Abdominoperineal Resection Defects
  118. One-level step section histological analysis is insufficient to confirm complete pathological response after neoadjuvant chemoradiation for rectal cancer
  119. Adverse events of self-expandable esophageal metallic stents in patients with long-term survival from advanced malignant disease
  120. Cyclooxygenase-2 gene polymorphisms and susceptibility to colorectal cancer in a Brazilian population
  121. Hand-assisted Approach as a Model to Teach Complex Laparoscopic Hepatectomies: Preliminary Results
  122. Risk Factors for Lymph Node Metastasis in Western Early Gastric Cancer After Optimal Surgical Treatment
  123. Diagnostic accuracy of probe-based confocal laser endomicroscopy in Lugol-unstained esophageal superficial lesions of patients with head and neck cancer
  124. GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE
  125. Integrated care pathway for rectal cancer treatment
  126. Efficacy of 3-Dimensional Endorectal Ultrasound for Staging Early Extraperitoneal Rectal Neoplasms
  127. Comparison of the pull and introducer percutaneous endoscopic gastrostomy techniques in patients with head and neck cancer
  128. Lymphoepithelioma-like gastric carcinoma: clinicopathological characteristics and infection status
  129. DETECTION OF OCCULT LYMPH NODE TUMOR CELLS IN NODE-NEGATIVE GASTRIC CANCER PATIENTS
  130. Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group
  131. Prognostic factors affecting outcomes in multivisceral en bloc resection for colorectal cancer
  132. Understanding the factors associated with reduction in the number of lymph nodes in rectal cancer patients treated by neoadjuvant treatment
  133. EVALUATION OF LYMPHATIC SPREAD, VISCERAL METASTASIS AND TUMORAL LOCAL INVASION IN ESOPHAGEAL CARCINOMAS
  134. PROGNOSTIC FACTORS AND SURVIVAL ANALYSIS IN ESOPHAGEAL CARCINOMA
  135. MINIMALLY INVASIVE SURGERY FOR GASTRIC CANCER: TIME TO CHANGE THE PARADIGM
  136. Pathologic Complete Response in Rectal Cancer
  137. ESOPHAGEAL CARCINOMA: IS SQUAMOUS CELL CARCINOMA DIFFERENT DISEASE COMPARED TO ADENOCARCINOMA? A transversal study in a quaternary high volume hospital in Brazil
  138. Obscure gastrointestinal bleeding caused by intestinal lipomatosis: double-balloon endoscopic and laparoscopic views
  139. Postoperative complications in the treatment of rectal neoplasia by transanal endoscopic microsurgery: a prospective study of risk factors and time course
  140. Argon plasma coagulation for the endoscopic treatment of gastrointestinal tumor bleeding: A retrospective comparison with a non‐treated historical cohort
  141. Predicting recurrence after curative resection for gastric cancer
  142. Detection value of free cancer cells in peritoneal washing in gastric cancer: a systematic review and meta-analysis
  143. Evaluation of microvessel density and p53 expression in pancreatic adenocarcinoma
  144. High occurrence of Fusobacterium nucleatum and Clostridium difficile in the intestinal microbiota of colorectal carcinoma patients
  145. Underwater endoscopic resection of a neuroendocrine rectal tumor
  146. Endoscopic stent for treatment of esophagojejunostomy fistula
  147. Endoscopic radial incision and cutting procedure for a colorectal anastomotic stricture
  148. Transfusion Requirements in Surgical Oncology Patients
  149. Endoscopic hemostasis of a bleeding gastric gastrointestinal stromal tumor (GIST) with endoloop placement
  150. Gastrointestinal stromal tumor of the rectum treated with neoadjuvant Imatinib followed by transanal endoscopic microsurgery
  151. Palliative laparoscopic resection of renal cell carcinoma metastatic to the stomach: report of a case
  152. Carnoy’s solution increases the number of examined lymph nodes following gastrectomy for adenocarcinoma: a randomized trial
  153. Carnoy's solution is an adequate tissue fixative for routine surgical pathology, preserving cell morphology and molecular integrity
  154. Asymptomatic Gastric Bacterial Overgrowth After Bariatric Surgery: Are Long-Term Metabolic Consequences Possible?
  155. A gene expression profile related to immune dampening in the tumor microenvironment is associated with poor prognosis in gastric adenocarcinoma
  156. Primary malignant melanoma of the esophagus: a rare and aggressive disease
  157. Percutaneous Transhepatic Biliary Drainage in Patients with Advanced Solid Malignancies: Prognostic Factors and Clinical Outcomes
  158. Epithelial Cell Turnover Is Increased in the Excluded Stomach Mucosa After Roux-en-Y Gastric Bypass for Morbid Obesity
  159. MOLECULAR MARKERS OF MUCOSA HARBORING GASTRIC ADENOMAS
  160. Etiology, endoscopic management and mortality of upper gastrointestinal bleeding in patients with cancer
  161. Resultados da gastrectomia D2 para o câncer gástrico: dissecção da cadeia linfática ou ressecção linfonodal múltipla?
  162. A novel approach for the treatment of pelvic abscess: transrectal endoscopic drainage facilitated by transanal endoscopic microsurgery access
  163. Endoscopic removal of migrated esophageal stent - the “grasper and pusher” method
  164. Isolated splenic metastasis from lung squamous cell carcinoma
  165. Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions
  166. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas
  167. Gastric secretory and hormonal patterns in end-stage chagasic achalasia
  168. Preoperative Gastric Acid Secretion and the Risk to Develop Barrett’s Esophagus After Esophagectomy for Chagasic Achalasia
  169. Barrett’s Esophagus and Carcinoma in the Esophageal Stump After Esophagectomy for Achalasia
  170. Mucin pattern reflects the origin of the adenocarcinoma in Barrett's esophagus: a retrospective clinical and laboratorial study
  171. Carnoy’s solution enhances lymph node detection: an anatomical dissection study in cadavers
  172. Single-use Trocar
  173. Barrett’s Esophagus (BE) and Carcinoma in the Esophageal Stump (ES) After Esophagectomy with Gastric Pull-Up in Achalasia Patients: A Study Based on 10 Years Follow-Up
  174. Secondary Lymphangiectasia of the Small Bowel: Utility of Double Balloon Enteroscopy for Diagnosis and Management
  175. Caffeic Acid Phenethyl Ester (CAPE) May be a Promising Adjuvant Treatment in Gastric Cancer
  176. Is double-balloon enteroscopy an accurate method to diagnose small-bowel disorders?
  177. Clinicopathologic and Immunohistochemistry Characterization of Synchronous Multiple Primary Gastric Adenocarcinoma
  178. What to Expect in the Excluded Stomach Mucosa after Vertical Banded Roux-en-Y Gastric Bypass for Morbid Obesity
  179. Prognostic value of immunohistochemistry in gastric neuroendocrine (carcinoid) tumors
  180. Free peritoneal tumour cells are an independent prognostic factor in curatively resected stage IB gastric carcinoma (Br J Surg 2006; 93: 325 –331)
  181. Does CO2 Pneumoperitoneum Alter the Ultra-Structuture of the Mesothelium?
  182. p53 na prática clínica: sim ou não?
  183. Does the Intraoperative Peritoneal Lavage Cytology Add Prognostic Information in Patients With Potentially Curative Gastric Resection?
  184. Interleukin-2-Activated Natural Killer Cells May Have a Direct Role in the Control of Leishmania (Leishmania) amazonensis Promastigote and Macrophage Infection.
  185. Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival
  186. Complications of gastrectomy with lymphadenectomy in gastric cancer
  187. Operative Versus Nonoperative Treatment for Stage 0 Distal Rectal Cancer Following Chemoradiation Therapy
  188. Participação da apoptose na rejeição aguda do transplante intestinal em ratos
  189. Estudo das alterações das citocinas inflamatórias na rejeição aguda do transplante intestinal em ratos
  190. Cell-mediated immune response in megacolon from patients with chronic chagas' disease
  191. Double pylorus: case report and review of the literature
  192. Activated Natural Killer Cell Tumor Retention and Cytokine Production in Colon Tumor Using a Tissue-Isolated Model
  193. Apoptosis In Esophageal Cancer Following Induction Chemoradiotherapy
  194. Low rectal cancer
  195. p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma
  196. Morphologic, histologic, and molecular similarities between adenocarcinomas arising in the gastric stump and the intact stomach
  197. Laparoscopic Removal of a Displaced Ventriculoperitoneal Shunt